Catalio Capital Management as of June 30, 2026
Portfolio Holdings for Catalio Capital Management
Catalio Capital Management holds 39 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Avalyn Pharmaceuticals Com Shs | 10.4 | $55M | 1.7M | 32.92 | |
| Johnson & Johnson (JNJ) | 6.6 | $35M | 139k | 253.97 | |
| Gilead Sciences (GILD) | 6.4 | $34M | 269k | 126.34 | |
| Bridgebio Pharma (BBIO) | 6.4 | $34M | 455k | 74.48 | |
| Syndax Pharmaceuticals (SNDX) | 5.0 | $27M | 1.2M | 21.86 | |
| Definium Therapeutics Com Shs (DFTX) | 5.0 | $27M | 563k | 47.04 | |
| Bristol Myers Squibb (BMY) | 4.5 | $24M | 413k | 57.62 | |
| Parabilis Medicines | 4.2 | $23M | 824k | 27.37 | |
| Natera (NTRA) | 4.2 | $22M | 82k | 271.45 | |
| Incyte Corporation (INCY) | 4.1 | $22M | 192k | 113.36 | |
| Septerna (SEPN) | 3.4 | $18M | 536k | 33.49 | |
| Mineralys Therapeutics (MLYS) | 3.3 | $18M | 649k | 26.98 | |
| Heartflow Inc/Sh (HTFL) | 3.2 | $17M | 583k | 29.34 | |
| Corvus Pharmaceuticals (CRVS) | 3.0 | $16M | 1.1M | 14.94 | |
| Structure Therapeutics Sponsored Ads (GPCR) | 2.8 | $15M | 277k | 53.67 | |
| Protagonist Therapeutics (PTGX) | 2.5 | $13M | 107k | 122.58 | |
| Disc Medicine (IRON) | 2.2 | $12M | 159k | 73.14 | |
| Edwards Lifesciences (EW) | 2.1 | $11M | 125k | 90.46 | |
| Axsome Therapeutics (AXSM) | 2.0 | $11M | 43k | 244.77 | |
| Ultragenyx Pharmaceutical (RARE) | 2.0 | $11M | 316k | 33.39 | |
| Kailera Therapeutics Common Stock | 1.9 | $10M | 469k | 22.03 | |
| Karyopharm Therapeutics Com New (KPTI) | 1.7 | $9.2M | 941k | 9.77 | |
| Odyssey Therapeutics Common Stock | 1.6 | $8.6M | 458k | 18.71 | |
| Ascendis Pharma A/s Ord Shs (ASND) | 1.6 | $8.5M | 32k | 266.72 | |
| Kardigan Ord | 1.4 | $7.5M | 313k | 23.85 | |
| Eledon Pharmaceuticals (ELDN) | 1.3 | $6.7M | 1.7M | 3.94 | |
| 4d Molecular Therapeutics In (FDMT) | 1.2 | $6.3M | 471k | 13.30 | |
| Veradermics Common Stock (MANE) | 1.1 | $5.6M | 46k | 122.94 | |
| Dyne Therapeutics (DYN) | 1.0 | $5.4M | 245k | 22.21 | |
| Fractyl Health (GUTS) | 0.9 | $4.9M | 6.2M | 0.79 | |
| Immunocore Hldgs Ads (IMCR) | 0.9 | $4.7M | 148k | 31.75 | |
| Dianthus Therapeutics (DNTH) | 0.6 | $3.2M | 33k | 97.48 | |
| Bridgebio Oncology Therapeut Com New (BBOT) | 0.5 | $2.4M | 318k | 7.62 | |
| Protara Therapeutics Com Stk (TARA) | 0.4 | $2.0M | 520k | 3.82 | |
| Hyperfine Com Cl A (HYPR) | 0.3 | $1.8M | 1.3M | 1.35 | |
| Ataibeckley Com Shs (ATAI) | 0.2 | $1.0M | 197k | 5.27 | |
| Metagenomi (MGX) | 0.1 | $630k | 529k | 1.19 | |
| Outset Med Com New (OM) | 0.1 | $511k | 118k | 4.32 | |
| Faeth Therapeutics Com New (FTH) | 0.1 | $368k | 15k | 25.00 |
